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Background: Bronchiectasis is the outcome of a number of different airway insults. Very few
studies have characterised the aetiology and utility of a dedicated screening proforma in adult
patients attending a general bronchiectasis clinic.
Methods: A prospective observational study of 189 bronchiectasis patients attending two cen-
tres in the North East of England over a two-year period was performed.
Results: The aetiology of bronchiectasis was identified in 107/189(57%) patients. Idiopathic
bronchiectasis (IB) represented the largest subgroup (43%). Post-infection bronchiectasis
(PIB) constituted the largest proportion (24%) of known causes. Mean age (SD) at diagnosis
was 54(20) years with a mean age at symptom onset of 37(24) years, accounting for a diag-
nostic delay of 17 years. Age of symptom onset was significantly younger in patients with
PIB compared to IB (p < 0.0001) and in Pseudomonas sputum positive patients (p Z 0.007).
Screening for APBA and total immunoglobulin deficiency identified 9 (5%) patients who then
had tailored treatment. Routine screening for other aetiologies was deemed unnecessary.of Respiratory Medicine, Galway University Hospitals, Galway, Ireland. Tel.: þ353 (0) 86 343 9047.
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1002 G.A. Anwar et al.Conclusion: IB and PIB accounted for two thirds of cases of bronchiectasis in a general popu-
lation. We recommend routine screening for ABPA and total immunoglobulin deficiency but not
for other rarer aetiologies.
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Bronchiectasis is a common, progressive respiratory disease
characterised by severe, recurrent bronchitis with resultant
high morbidity and reduced quality of life.1 Importantly,
bronchiectasis often goes unrecognised even when char-
acteristic features are present and appropriate diagnostic
techniques are readily available.2
The management of bronchiectasis centres on two main
pillars e sputum clearance and judicious use of antibiotics.
Identifying the cause of bronchiectasis, however, may
refine management further, e.g. in immunodeficiency
states, ABPA and recurrent aspiration.
Most of the data on the causes of bronchiectasis come
from tertiary or quartenary referral centres where there
may be a selection bias towards more complex aetiologies.
Very few studies have characterised the cause of disease in
a large population of adult patients with bronchiectasis
attending general bronchiectasis clinics. Moreover, the
value and relevance of performing extensive screening in-
vestigations to phenotype bronchiectasis patients has not
been evaluated.
The objectives of our study were to: 1) review the
aetiology in a large cohort of adult bronchiectasis patients
in the North East of England; 2) determine how often
making a specific diagnosis leads to a change in manage-
ment; and 3) assess the relevance of specific screening
tests in the diagnostic work-up of bronchiectasis.
Methods
Our study population consisted of outpatients attending
two general bronchiectasis clinics in the North East of En-
gland. Patients with traction bronchiectasis related to
interstitial lung disease were excluded. The study was
performed prospectively over a two-year period (October
2006 to August 2008). Ethical approval was obtained from
our local ethics committee. The recommendations of
STROBE in relation to the reporting of this observational
study were followed.3
Bronchiectasis phenotyping
A comprehensive history was recorded including: age at
symptom onset and diagnosis; total duration of symptoms;
previous acute respiratory illnesses and temporal relation-
ship with onset of bronchiectasis symptoms; history of
autoimmune disease, inflammatory bowel disease (IBD),
gastro-oesophageal reflux disease, aspiration, inhaled
foreign body, rhinosinusitis and middle ear disease; smoking
history; fertility; previous diagnosis of COPD and asthma;
and symptoms relating to possible immunodeficiency.Investigations
The following were tested: Serum immunoglobulins IgG,
IgA, IgM, IgE and IgG subclasses; specific antibodies to
Haemophilus influenza B (HIB) and Streptococcus pneu-
monia antigens-repeated 6 weeks after vaccination to
assess response if initially low; Aspergillus IgG precipitins
plus Aspergillus skin prick test if positive; peripheral blood
eosinophilia and serum IgE level; rheumatoid factor and
autoantibody screen; alpha-1-antitrypsin (A1AT) levels with
phenotype if low; sputum culture and AFB smear and
culture.
Cystic Fibrosis (CF) screening was performed in patients
with suspected idiopathic bronchiectasis (IB) and any high
risk patients with suggestive features such as symptoms
since childhood, upper lobe disease; persistent Staphylo-
coccal aureus or Pseudomonas aeruginosa (PA) growth,
and/or history of infertility.
Patients were referred to the Regional Specialist Centre
for investigation of Primary Ciliary Dyskinesia (PCD) if there
was a history of childhood otitis media, marked history of
rhinosinusitis and/or infertility.
Radiology: The diagnosis of bronchiectasis was
confirmed by standard high-resolution computed tomogra-
phy (HRCT) criteria.4,5 All scans were assessed initially by
radiologists with expertise in high resolution cross-sectional
imaging and confirmed by a single dedicated thoracic
radiologist.
Pulmonary function tests (PFTs): Spirometry was per-
formed in all patients allowing calculation of Forced Expi-
ratory Volume in one second (FEV1), Forced Vital Capacity
(FVC), and FEV1/FVC ratio. All PFTs were carried out by
physiologists trained according to the recommendations of
the European Respiratory Society (ERS).6 FEV1 and FVC
were expressed as absolute values and percent predicted
for age, sex, and height employing ERS reference ranges.7Aetiology of bronchiectasis
Post-infective bronchiectasis (PIB) was diagnosed in pa-
tients reporting a history of symptom onset within 10 years
of a severe respiratory tract infection, such as pneumonia,
whooping cough or complicated measles infection. Post-
tuberculous bronchiectasis was diagnosed in patients with
clearly documented prior tuberculosis and compatible
radiology. Bronchiectasis associated with rheumatoid
arthritis (RA) or IBD was diagnosed in patients with definite
symptom onset of bronchiectasis following confirmed
diagnosis of these diseases. Causation secondary to asthma
or COPD was attributed when bronchiectasis symptoms
were reported to develop >5 years after the initial primary
diagnosis. Young’s syndrome was diagnosed when there was
Table 2 Aetiological causes of bronchiectasis.
Cause n (% of total)
Idiopathic bronchiectasis 82 (43)
Post-infectious bronchiectasis 46 (24)
Chronic obstructive pulmonary disease 23 (12)
Rheumatoid arthritis 9 (5)
Allergic broncho-pulmonary aspergillosis 7 (4)
Asthma 6 (3)
Ulcerative colitis 5 (2)
Alpha-1 anti-trypsin deficiancy 2 (1)
Aspiration/gastro-oesophageal reflux 2 (1)
Primary ciliary dyskinesia 2 (1)
Common variable immunodeficiency 2 (1)
Pink’s disease 1 (<1)
Young’s syndrome 1 (<1)
Cystic fibrosis 1 (<1)
Foreign body inhalation 0 (0)
Total 189
Phenotyping adults with non-cystic fibrosis bronchiectasis 1003a history of bronchiectasis, sinusitis and azoospermia in
males and negative CF testing.8 Pink’s disease was diag-
nosed based on a history of mercury poisoning in childhood.
A serum IgE of >1000 IU/ml, positive Aspergillus precipitins
and skin prick, blood eosinophilia of >0.4 and compatible
radiology was required to fulfil the diagnosis of ABPA. A
diagnosis of IB was made by exclusion of any known cause.
Statistical analysis
Statistics were computed using SPSS Version 17. Simple
descriptive statistics including mean and standard deviation
were used for continuous parametric data, median and
interquartile range for continuous non-parametric data,
and frequencies and percentages for categorical data.
Comparisons of clinical features amongst the study sub-
groups were carried out using non-parametric Mann Whit-
ney test for ordinal data or Fisher exact test for nominal
data. Subgroup analyses were performed using Chi-Square
and/or cross tabulations to compare proportions of
observed and expected frequencies of relevant variables.
The appropriate test was chosen according to group size
and distribution. A p-value <0.05 was considered statisti-
cally significant.
Results
230 patients were recruited to the study based on initial
HRCT reports of presumed bronchiectasis. Following inde-
pendent review, 41(18%) patients were deemed to have
inadequate findings to support a diagnosis of bronchiectasis
and were excluded. Baseline demographics of the remain-
ing 189 bronchiectasis patients are shown in Table 1.
Table 2 summarises the aetiological breakdown. IB was
the largest subgroup (43%). PIB constituted the largest
proportion (24%) of known causes.
Mean age (SD) at diagnosis was 54(20) years. Mean age at
symptom onset was 37(24) years, accounting for a diag-
nostic delay of 17 years. Subgroup analyses were performed
to assess differences based on phenotype and PA status
(Table 3). Age of symptom onset was significantly younger
in patients with PIB compared to IB (p < 0.0001) and, across
all aetiological groups, in those who were ever PA-positive
(p Z 0.007). Table 4 compares clinical history with
phenotype.Table 1 Baseline demographics of the study population.
Demographics n (%)
Total number of patients 189
Age mean in years (range) 66.11 (24e89)
Female (%) 95 (51.3%)
Smokers (10 pack years) 62 (32.8%)
Current smokers 7 (3.7)
FEV1%, mean (SD) 67.08 (24.07)
FVC%, mean (SD) 82.61 (21.87)
Ratio %, mean (SD) 65.62 (13.23)
FEV1Z Forced Expiratory Volume in one second; FVCZ Forced
Vital Capacity.Outcome of screening tests in bronchiectasis
ABPA (nZ 7): 164(87%) patients were tested for Aspergillus
precipitins with positive results in 44(27%). Aspergillus skin
prick test was performed in 61(32%) patients with 11(18%)
positive. 51(27%) patients had both tests performed with
positive results in 8(15.4%).
Immunodeficiency (Table 5): 4(2%) patients were found
to have combined immunoglobulin deficiencies: two with
secondary immune deficiency (due to RA and chronic lym-
phocytic leukaemia), both of whom were commenced on
regular immunoglobulin replacement therapy; and two with
mild reductions in IgG and IgM, attributed to long-term glu-
cocorticoids. No significant differences in immunoglobulin
levels on subgroups analyses comparing IB, non-idiopathic
bronchiectasis (NIB), and PIB phenotypes. A significantly
higher proportion of females had low levels of IgM. Of 58 PA-
positive patients, 18(31%) were found to have low IgM levels
(3 males, 15 females) compared to 19(16%) of 121 patients
whose sputum was never PA-positive (pZ 0.018).
161(85%) patients underwent functional antibody
testing. 79(49%) had initially low antibodies to HIB. 36(46%)
underwent vaccination with HIB and in all of these patients
antibodies normalised. 5(3%) patients had low antibody
levels to S. pneumonia 23 valent vaccine antigens; all
normalised after Pneumovax vaccination. The remaining
immunoglobulin deficiencies were sporadic and patients
were subsequently deemed immunocompetent following
specialist immunology review.
Autoimmune disease (n Z 16): 185(98%) patients were
tested for rheumatoid factor and this was positive in 28(15%)
of patients, 9 ofwhomhadRA-associated bronchiectasis. 179
patients underwent auto-antibody screening with 13(7%)
positive for anti-nuclear factor, all negative for extractable
nuclear antigens andnonewith a connective tissue disease. 5
patients had a pre-existing diagnosis of ulcerative colitis
before onset of bronchiectasis symptoms with no other
causative factor found. 1 patient developed ulcerative co-
litis many years after developing bronchiectasis, 1 had
coeliac disease and 1 had autoimmune thyroid disease.
Table 4 Comparison of clinical history based on phenotype.
History Total
(n Z 189)
IB
(n Z 82)
NIB
(n Z 107)
p-value (IB vs NIB) PIB
(n Z 46)
p-value (IB vs PIB)
Childhood infection (%) 95 (50) 31 (38) 64 (60) 0.003 36 (78) 0
Childhood pneumonia (%) 46 (24) 8 (10) 38 (35) <0.0001 24 (52) 0
Adult pneumonia (%) 33 (17) 12 (15) 21 (20) 0.372 8 (17) 0.681
Measles (%) 53 (28) 18 (22) 35 (33) 0.104 18 (39) 0.039
Whooping cough (%) 46 (24) 14 (17) 32 (30) 0.042 21 (46) 0.001
Tuberculosis (%) 12 (6) 0 12 (11) 0.002 8 (17) 0
Heartburn (%) 62 (32) 26 (31) 36 (33) 0.779 15 (33) 0.917
Family History (%) 5 (3) 4 (5) 1 (1) 0.043 0 0.087
Lobectomy (%) 21 (11) 5 (6) 16 (15) 0.056 13 (28) 0.001
PND/Rhinitis (%) 67 (35) 26 (31) 41 (38) 0.348 23 (50) 0.042
Smoking >10 pack years (%) 62 (33) 16 (19) 46 (43) 0.001 13 (28) 0.258
IB Z Idiopathic bronchiectasis; NIB Z non-idiopathic bronchiectasis; PIB Z Post-infectious bronchiectasis.
Table 3 Comparison of temporal relationship of symptom onset, duration and age at diagnosis based on:
a) Phenotype
Age parameters, mean (SD) Phenotype
IB
(n Z 82)
NIB
(n Z 107)
p-value (IB vs NIB) PIB
(n Z 46)
p-value (IB vs PIB)
Age at symptom onset 42 (23) 33 (25) 0.012 19 (21) <0.0001
Age at diagnosis 55 (20) 53 (21) 0.533 45 (26) 0.106
Total symptom duration 23 (20) 31 (24) 0.025 47 (22) <0.0001
b) Sputum PA status
Age parameters, mean (SD) Sputum Pseudomonas status
Positive Negative p-value
Age at symptom onset 30 (25) 41 (23) 0.007
Age at diagnosis 48 (22) 56 (19) 0.045
Total symptom duration 36 (22) 23 (21) <0.0001
IB Z Idiopathic bronchiectasis; NIB Z non-idiopathic bronchiectasis; PIB Z Post-infectious bronchiectasis.
1004 G.A. Anwar et al.Alpha 1 Antitrypsin (A1AT) Deficiency (n Z 2):
169(89%) patients were tested for A1AT deficiency; only 2
were identified as having bronchiectasis secondary to mild
A1AT deficiency (A1AT levels 0.9 and 0.8 g/l).
Cystic Fibrosis (n Z 1): 100(52.9%) patients were
screened for CF, 65(79%) in the IB subgroup and 35 in theTable 5 Comparison of diagnostic delay between bron-
chiectasis subgroups.
Subgroup Age range Diagnostic
delay (years)
Idiopathic
bronchiectasis
66.0 (24e89) 13
Non-idiopathic
bronchiectasis
66.2 (31e89) 20
Post-infectious
bronchiectasis
66.2 (31e84) 26
Total cohort 66.1 (24e89) 17NIB subgroup. 94 patients had genetic CFTR testing, 6 with
the sweat test alone, and 12 with both. A single mutation
was identified in 4 patients (all IB) but all had a normal
sweat test. One patient from the NIB subgroup was found to
be compound heterozygous and was diagnosed with CF at
the age of 82 years.Establishment of disease aetiology and clinical
management
Establishment of an aetiological diagnosis resulted in a
specific change in management in 14(7%) patients: ABPA(7),
immunoglobulin deficiency(2), aspiration(2), PCD(2) and
CF(1).Discussion
189 patients with confirmed bronchiectasis were reviewed
and their aetiological factors characterised. A cause of
Table 6 Immunoglobulin counts (percentage) of patients
with normal, high or low levels.
Ig Total (%) Normal (%) High (%) Low (%)
IgG 183 (97) 159 (87) 14 (8) 10 (5)
IgA 187 (99) 132 (70) 51 (27) 4 (2)
IgM 187 (99) 142 (75) 8 (4) 37 (20) 31fm,
6m (p<0.0001)
IgG1 159 (84) 152 (96) 6 (4) 1 (<1)
IgG2 160 (85) 157 (98) 3 (2) 0
IgG3 161 (85) 112 (70) 49 (30) 0
IgG4 159 (84) 156 (98) 3 (2) 0
Ig Z immunoglobulin.
Phenotyping adults with non-cystic fibrosis bronchiectasis 1005bronchiectasis was identified in 107(57%) of patients. This
affected management in only 14(7%) patients. Few studies
have looked at a detailed breakdown of aetiology and
phenotyping in adult bronchiectasis patients (Table 5).9e11
Our cohort is one of the largest studies to date and theTable 7 Comparison of available phenotyping studies in adult b
Aetiological study Pasteur et al. 20009 King et al.
Number of patients 150 103
Diagnosis of
bronchiectasis
HRCT HRCT (95)
Bronchogra
Mean age (SD) 52.7 (15.2) 56 (14)
Male:female ratio % 38:62 37:63
Idiopathic bronchiectasis % 53 74
Post-infectious
bronchiectasis %
29 10
ABPA % 7 4
Immunoglobulin
deficiency %
8 ?
IgG subclass deficiency % <1 9 (IgG2 low
2 and IgG3
in 7 patient
Rheumatoid arthritis 3 2
Ulcerative colitis 1 e
Cystic fibrosis 3 None
Ciliary dysfunction % 1.5 (PCD) 1 (Kartagen
syndrome)
Young’s syndrome % 3 1
Aspiration 4 None
Panbronchiolitis <1 None
Congenital <1 None
A1AT deficiency (%) 0 None
Others e e
SDZ standard deviation; ABPAZ allergic bronchopulmonary aspergillfirst to describe the aetiology of bronchiectasis among an
unselected patient cohort attending general bronchiectasis
clinics. As such, it may reduce bias related to patient
referral to tertiary and quartenary care settings and render
the results more generalisable (Tables 6 and 7).
Our study broadly agreedwith previouswork in that 43% of
our cohort had IB and 24% had PI bronchiectasis, similar to
that of 53% and 29% respectively in the Pasteur study.9 Pre-
vious studies have reported IB to range from 26 to 74% and PI
bronchiectasis from 10 to 32% depending on study criteria
used to define disease.2,9e12 Establishing a diagnosis of PIB is
extremely difficult as the herald event often took placemany
decades before and is therefore prone to both negative and
positive recall bias. It can also be very difficult to determine
the severity of the initial infection and the temporal rela-
tionship to subsequent infections. Indeed, there is no defi-
nition as to what constitutes post-infection bronchiectasis in
terms of time between initial insult and emergence of
recurrent airway sepsis. We arbitrarily chose a post-infection
symptom free period of 10 years as excluding the infection as
causal. Employing this definition, our PI bronchiectasisronchiectasis.
200610 Shoemark et al. 200711 Current study
165 (out of 240) 189 (out of 230)
HRCT HRCT
phy(8)
49 (16) 66.1 (11.5)
35:65 94:95
26 43
32 24.3
8 7
7 2
in
s)
None 1 (deficient in IgG1)
2 9
3 5
1 1
er’s 10 (n Z 17), definite
PCD (n Z 12), probable
PCD (n Z 5)
2 (Definite PCD)
3 (n Z 5) (3 _ with
obstructive
azoospermia þ 2 \
with pink’s
disease as babies
1 (n Z 2) (1 _ with
obstructive
azoospermia þ 1 \ with
pink’s disease as babies
1 2
2 None
e e
None 2
Mycobacterium
infection Z 2
Asthma Z 6
Yellow nail
syndrome Z 2
COPD Z 23
osis; IgGZ Immunoglobulin class G; A1ATZ alpha-1 anti-trypsin.
1006 G.A. Anwar et al.patients had a significantly younger age at symptom onset
compared to IB (19 vs 42 years, p < 0.0001) suggesting a
different disease process.
It is very interesting to note that over a third of patients
with IB reported a significant childhood infection and a
quarter had had either a childhood or adult pneumonia
suggesting a general propensity to pulmonary infection.
Summing IB and PIB in published bronchiectasis series, pro-
duces similar results: 82%,9 82%,11 90%13 and 82%.14 The total
in the present study together accounted for two-thirds of
causes of bronchiectasis. Shoemark et al., reported signifi-
cant differences between IB and PIB in terms of increased
likelihood of lower lobe involvement, older age at onset,
greater prevalence of chronic rhinosinusitis, and chronicity
of symptoms from onset in the former.1 Our study concurred
with age of symptom onset and symptom chronicity but
interestingly, chronic rhinosinusitus was significantly more
common in PIB than IB (50% vs 31%, pZ 0.042).
The demographics of our cohort revealed some inter-
esting observations. There were equal numbers of male and
females in the whole cohort and IB and NIB subgroups which
is in contrast to other studies showing a marked female
predominance.2,10,11,15,16 Only one other recent study of
aetiological causes of bronchiectasis in children also
showed equal gender distribution.17 Our higher proportion
of males in IB is not readily explainable but may represent a
regional genetic predisposition or higher chronic exposure
to airway irritants as our region is associated with heavy
industry and low socio-economic status. Our higher pro-
portion of males in NIB may relate to our high prevalence of
COPD (12%) compared to 5% reported by King et al.10
All groups showed marked delays from symptom onset to
diagnosiswith an average delay of 17 years. This is fascinating
given that excellent non-invasive diagnostic techniques have
been widely available for approximately two decades sug-
gesting that index of suspicion for this condition remains low.
It is interesting that age at diagnosis was significantly earlier
in PA-positive patients, almost certainly due to more severe
disease in this subgroup. The cause of delay may possibly be
explained on the basis of symptoms becoming more marked
only as the disease progresses.11 There is also a general
misconception that bronchiectasis is now a rare disease and,
indeed, is frequently classified as an orphan lung disease. It is
also possible that the rapid expansion of COPD and asthma
chronic disease management programs has diverted atten-
tion away from this poorer cousin of the airway diseases and
also resulted in mislabelling of the disease as one of these
commoner conditions.
With regards to establishing the aetiology of bronchiec-
tasis and the relevance of screening tests, we wish to make
several comments. A detailed history remains crucial in
differentiating IB from PIB and determining whether bron-
chiectasis is primary, or secondary to established obstruc-
tive lung disease or autoimmune disease such as RA or UC.
Whether this ultimately affects management is contentious
but it could be argued that “splitting” rather than “lump-
ing” is more likely to lead to tailored treatment in the
future. We would argue that routine screening should only
consist of testing for ABPA and total IgG, IgA and IgM levels.
ABPA and combined immunodeficiency accounted for 5% of
cases in our cohort and both can be specifically treated. We
found no additional diagnostic yield in testing IgGsubclasses. Indeed, Shoemark et al. abandoned IgG subclass
testing due to persistently normal levels in their popula-
tion.11 Certain IgG subclasses may also be completely ab-
sent in normal healthy people, there are difficulties in
defining normal ranges.18 Interestingly, King et al. found no
evidence of hypogammaglobulinemia in 103 participants
but did find a significant level of IgG3 deficiency.10
Our finding of isolated low IgM levels in a significantly
large number of females and PA-positive patients has never
been reported in the literature and should be viewed with
caution. The laboratory normal ranges for serum IgM for our
local population reveals a lower limit of normal for females
of almost three times higher than that of males (0.71 g/l vs
0.24 g/l). In all populations, IgM levels are higher in females
than males.19,20 Most low serum IgM levels in our study were
not severely low with many of these patients found to be
immunocompetent on further testing. Severe selective IgM
deficiency is associated with increased susceptibility to in-
fections, but mild abnormalities are poorly understood.19,20
IgM as a protective antibody becomes less important in late
adult life as most infections are dealt with by a brisk IgG
response.19,20 This switch over to IgG as the main antibody
may result in less IgM being produced. Similarly, whilst a
number of patients had low initial levels of functional anti-
bodies to HIB and S. pneumonia, all those vaccinated
mounted appropriate responses, hence we would not
recommend routine functional antibody testing. However,
this could be considered in patients with documented pre-
vious Streptococcus or HIB pneumonia, marked co-existent
sinusitis or repeated gastroenteritis.
We found testing for rheumatoid factor and auto-
antibodies of no clinical value as most patients with posi-
tive findings already had a clinical diagnosis of RA or UC.
Nearly 10% of our population were rheumatoid factor posi-
tive with no clinical evidence of RA. Hilton et al. also found
over half of 53 IB patients to have positive rheumatoid factor
suggesting it is an epi-phenomenon of chronic immune
stimulation and in no way predictive of developing RA.21
Previous studies have shown that only patients with
severely deficient AIAT levels have associated bronchiec-
tasis.22 We identified 2 patients with mild deficiency and it is
unclear whether this is causative, or more likely, a chance
association, given the high prevalence of heterozygosity in
the population. This fact, coupled with the absence of
proven therapy for mild deficiency, suggests that routine
testing for AIAT deficiency is unwarranted and should only be
conducted if suspicious of severe homozygous disease.9e11
Shoemark performed CF screening on 165 patients and
identified 2 patients (1%) with CF.11 Our finding of one CF
patient in 100 screened is in accordance with background
carrier frequency. Given the low pick-up rate and the
expense of testing, we would not recommend routine CF or
PCD screening and reserve testing for selected cases.
In summary, we identified a cause of bronchiectasis in
107/189(57%) patients. This affected management in only
14(7%) patients. Despite the array of investigative tests
available, we conclude that history is the most important
investigative tool at our disposal. Following comprehensive
analysis of screening tests commonly performed in the diag-
nostic work-up of bronchiectasis, we conclude that routine
screening should only consist of testing forABPAand total IgG,
IgA and IgM levels.
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